Goto Biopharm's subsidiary plans to purchase assets required for production and operation from YuanKe Biotechnology for no more than RMB 16.5703 million
I'm PortAI, I can summarize articles.
Goto Biopharm's wholly-owned subsidiary, Hubei Goto Biotechnology Co., Ltd., intends to purchase land and attachments necessary for production and operation from Hubei Yuanke Biomedical Technology Co., Ltd., with a transaction amount not exceeding 16.5703 million yuan. The asset will be used for projects such as the construction of a sewage treatment facility and Class A workshops. The two parties will sign a transfer agreement after completing the approval procedures
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments